Scil Technology Files Patent on Coating
Technology for Implants
MARTINSRIED, Germany, May 5, 2004 – Scil
Technology, a biopharmaceutical company focused on the development
of dental tissue regeneration products, today announced it
has extended its IP portfolio by a further patent application.
The technology claimed in this application allows coating
of medical implants like screws, nails, stents etc. with active
pharmaceutical compounds, especially recombinant proteins.
The process, which retains the native structure and activity
of a protein when directly coated onto the surface of a metal
implant is easily transferable to large scale aseptic manufacturing.
The Company plans to use this technology in the first instance
for the commercial, cost effective manufacturing of regenerative,
growth factor activated dental implants. These will be developed
for patients who have a risk for lower dental implant success
rates because of their poor jaw bone quality caused by insufficient
oral hygiene, heavy smoking, osteoporosis or insufficiently
treated diabetes associated with high blood sugar level.
In addition to the activated dental implants the technology
could also be applied to orthopaedic implants for various applications.
Dr Irina Staatz-Granzer, Managing Director of Scil Technology,
commented:
“Scil Technology has pioneered this unique coating technology, which will
allow us to develop regenerative, activated implants that actually facilitate
the osseointegration of the respective implants.”
About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development
company focused on dental and orthopaedic tissue regeneration
with a particular emphasis on bone and cartilage repair. The
Company’s lead therapeutic candidates are based on recombinant,
highly specific human growth factors. These are combined with
biodegradable biomaterials to generate local application forms.
Scil Technology’s pipeline for dentistry includes products
that are targeted at periodontal disease, dental implantology
and maxillofacial surgery. Orthopaedic products are developed
for spinal fusion, traumatic lesions of bone and cartilage
tissue and osteoarthritis. Scil Technology has emerged
from the Scil Group and is located in the biotechnology cluster
in Martinsried, Germany.
For more information please visit: http://www.scil.com
Contacts
Media relations:
Sue Charles, MA, MBA, CEO
Northbank Communications
t : +44 (0) 20 7886 8152
e: s.charles@northbankcommunications.com
Douglas Pretsell, Ph.D., Senior Account Manager
Northbank Communications
t : +44 (0) 20 7886 8158
e: d.pretsell@northbankcommunications.com
At Scil Technology:
Dr Irina Staatz-Granzer, Managing Director
Scil Technology GmbH
t: +49 (0)89 85651824
e: irina.staatz@scil.com
|
